Cargando…

A Systematic Review of Pharmacological Interventions for Apathy in Aging Neurocognitive Disorders

Objective: Apathy, a frequent neuropsychiatric symptom in aging neurocognitive disorders, has been associated with cognitive decline and functional disability. Therefore, timely provision of pharmacological interventions for apathy is greatly needed. Design: A systematical literature review of exist...

Descripción completa

Detalles Bibliográficos
Autores principales: Theleritis, Christos, Siarkos, Kostas, Politis, Anastasios, Smyrnis, Nikolaos, Papageorgiou, Charalabos, Politis, Antonios M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377475/
https://www.ncbi.nlm.nih.gov/pubmed/37508993
http://dx.doi.org/10.3390/brainsci13071061
_version_ 1785079526981632000
author Theleritis, Christos
Siarkos, Kostas
Politis, Anastasios
Smyrnis, Nikolaos
Papageorgiou, Charalabos
Politis, Antonios M.
author_facet Theleritis, Christos
Siarkos, Kostas
Politis, Anastasios
Smyrnis, Nikolaos
Papageorgiou, Charalabos
Politis, Antonios M.
author_sort Theleritis, Christos
collection PubMed
description Objective: Apathy, a frequent neuropsychiatric symptom in aging neurocognitive disorders, has been associated with cognitive decline and functional disability. Therefore, timely provision of pharmacological interventions for apathy is greatly needed. Design: A systematical literature review of existing studies was conducted up to 30 May 2023 in several databases (PubMed, PsychInfo, Cochrane, Google Scholar, etc.) that included randomized controlled trials (RCTs) and meta-analyses assessing pharmacological treatments for apathy in aging neurocognitive disorders. The quality of the studies was appraised. Results: In patients with Alzheimer’s Disease (AD), donepezil, galantamine, rivastigmine, methylphenidate, and gingko biloba were proven efficacious for apathy, while rivastigmine, cognitive enhancer IRL752 and piribedil were found to be beneficial in patients with Parkinson’s Disease (PD) and agomelatine in patients with Frontotemporal Dementia (FD). The extensive proportion of RCTs in which apathy was used as a secondary outcome measure, along with the considerable methodological heterogeneity, did not allow the evaluation of group effects. Conclusions: Pharmacological interventions for apathy in aging neurocognitive disorders are complex and under-investigated. The continuation of systematic research efforts and the provision of individualized treatment for patients suffering from these disorders is vital.
format Online
Article
Text
id pubmed-10377475
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103774752023-07-29 A Systematic Review of Pharmacological Interventions for Apathy in Aging Neurocognitive Disorders Theleritis, Christos Siarkos, Kostas Politis, Anastasios Smyrnis, Nikolaos Papageorgiou, Charalabos Politis, Antonios M. Brain Sci Review Objective: Apathy, a frequent neuropsychiatric symptom in aging neurocognitive disorders, has been associated with cognitive decline and functional disability. Therefore, timely provision of pharmacological interventions for apathy is greatly needed. Design: A systematical literature review of existing studies was conducted up to 30 May 2023 in several databases (PubMed, PsychInfo, Cochrane, Google Scholar, etc.) that included randomized controlled trials (RCTs) and meta-analyses assessing pharmacological treatments for apathy in aging neurocognitive disorders. The quality of the studies was appraised. Results: In patients with Alzheimer’s Disease (AD), donepezil, galantamine, rivastigmine, methylphenidate, and gingko biloba were proven efficacious for apathy, while rivastigmine, cognitive enhancer IRL752 and piribedil were found to be beneficial in patients with Parkinson’s Disease (PD) and agomelatine in patients with Frontotemporal Dementia (FD). The extensive proportion of RCTs in which apathy was used as a secondary outcome measure, along with the considerable methodological heterogeneity, did not allow the evaluation of group effects. Conclusions: Pharmacological interventions for apathy in aging neurocognitive disorders are complex and under-investigated. The continuation of systematic research efforts and the provision of individualized treatment for patients suffering from these disorders is vital. MDPI 2023-07-12 /pmc/articles/PMC10377475/ /pubmed/37508993 http://dx.doi.org/10.3390/brainsci13071061 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Theleritis, Christos
Siarkos, Kostas
Politis, Anastasios
Smyrnis, Nikolaos
Papageorgiou, Charalabos
Politis, Antonios M.
A Systematic Review of Pharmacological Interventions for Apathy in Aging Neurocognitive Disorders
title A Systematic Review of Pharmacological Interventions for Apathy in Aging Neurocognitive Disorders
title_full A Systematic Review of Pharmacological Interventions for Apathy in Aging Neurocognitive Disorders
title_fullStr A Systematic Review of Pharmacological Interventions for Apathy in Aging Neurocognitive Disorders
title_full_unstemmed A Systematic Review of Pharmacological Interventions for Apathy in Aging Neurocognitive Disorders
title_short A Systematic Review of Pharmacological Interventions for Apathy in Aging Neurocognitive Disorders
title_sort systematic review of pharmacological interventions for apathy in aging neurocognitive disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377475/
https://www.ncbi.nlm.nih.gov/pubmed/37508993
http://dx.doi.org/10.3390/brainsci13071061
work_keys_str_mv AT theleritischristos asystematicreviewofpharmacologicalinterventionsforapathyinagingneurocognitivedisorders
AT siarkoskostas asystematicreviewofpharmacologicalinterventionsforapathyinagingneurocognitivedisorders
AT politisanastasios asystematicreviewofpharmacologicalinterventionsforapathyinagingneurocognitivedisorders
AT smyrnisnikolaos asystematicreviewofpharmacologicalinterventionsforapathyinagingneurocognitivedisorders
AT papageorgioucharalabos asystematicreviewofpharmacologicalinterventionsforapathyinagingneurocognitivedisorders
AT politisantoniosm asystematicreviewofpharmacologicalinterventionsforapathyinagingneurocognitivedisorders
AT theleritischristos systematicreviewofpharmacologicalinterventionsforapathyinagingneurocognitivedisorders
AT siarkoskostas systematicreviewofpharmacologicalinterventionsforapathyinagingneurocognitivedisorders
AT politisanastasios systematicreviewofpharmacologicalinterventionsforapathyinagingneurocognitivedisorders
AT smyrnisnikolaos systematicreviewofpharmacologicalinterventionsforapathyinagingneurocognitivedisorders
AT papageorgioucharalabos systematicreviewofpharmacologicalinterventionsforapathyinagingneurocognitivedisorders
AT politisantoniosm systematicreviewofpharmacologicalinterventionsforapathyinagingneurocognitivedisorders